<![CDATA[Belzutifan Combo Exhibits Comparable HRQoL Vs Cabozantinib in RCC]]>

Data ReadoutpositivebelzutifanlenvatinibcabozantinibPositive

AI Analysis

Summary

Belzutifan in combination with lenvatinib demonstrated comparable health-related quality of life outcomes to cabozantinib in patients with previously treated renal cell carcinoma.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Health-related quality of life was comparable between belzutifan plus lenvatinib and cabozantinib in previously treated renal cell carcinoma patients

Importance:5/10

Sentiment:

0.60

renal cell carcinomaquality of lifecombination therapyclinical data

Related Companies

$HIT

Read the original article

Published by Cancer Network on July 27, 2026 3:00 PM

Read Original